BBIO NASDAQ
BridgeBio Pharma, Inc.
1W: +0.9%
1M: -5.6%
3M: +3.1%
YTD: -10.2%
1Y: +108.5%
3Y: +398.8%
5Y: +31.0%
$69.12
-1.16 (-1.65%)
Weekly Expected Move ±6.1%
$58
$62
$66
$70
$74
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
1 bullish
0 neutral
0 bearish
Articles (7d)
1
Daily Sentiment (7 Days)
Articles (92)
BioMarin's Voxzogo Meets Goal in Late-Stage Study for Hypochondroplasia
Evercore ISI Retains an “Outperform Rating” on BridgeBio Pharma, Inc. (BBIO)
BridgeBio Submits NDA to FDA for Encaleret for Individuals Living with ADH1
Acoramidis Continues to Demonstrate Disease-Modifying Effects in ATTR-CM, Reducing sTTR Variability and Outpatient Worsening Heart Failure
BridgeBio outlines $500M share repurchase as it targets P&L breakeven in 2027
BridgeBio (BBIO) Q1 2026 Earnings Transcript
BridgeBio Pharma (BBIO) Reports Q1 Loss, Tops Revenue Estimates
BridgeBio Pharma GAAP EPS of -$0.84 misses by $0.16, revenue of $194.5M beats by $15.89M
BridgeBio Reports First Quarter 2026 Financial Results and Corporate Updates
Here are the major earnings after the close Thursday
BridgeBio to Participate in May and June Investor Conferences
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
BridgeBio to Present Primary Results from the Phase 3 CALIBRATE Trial at 2026 ECE
Gartner Gears Up to Report Q1 Earnings: What's in the Offing?
IQVIA Set to Report Q1 Earnings: Here's What You Should Know
BridgeBio to Present New Acoramidis Data on Disease Progression, Biomarkers, and Clinical Outcomes at ESC-Heart Failure 2026
BridgeBio to Report First Quarter 2026 Financial Results and Commercial Updates on May 7, 2026 at 4:30 pm ET
Amphastar Pharmaceuticals (AMPH) Expected to Beat Earnings Estimates: Should You Buy?
BridgeBio (BBIO) Q2 2025 Earnings Transcript
Will BridgeBio Pharma (BBIO) Report Negative Q1 Earnings? What You Should Know
BridgeBio gains after settlement in Pfizer Vyndamax patent dispute
BridgeBio Launches Health Education Effort on Often Overlooked Heart Condition Featuring Attruby® Advocates, Morgan Freeman and Sports Business Icon Howard H. White
B. Metzler seel. Sohn & Co. AG Cuts Position in BridgeBio Pharma, Inc. $BBIO
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Rep. Gilbert Ray Cisneros, Jr. Buys BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares
ClearBridge SMID Cap Growth strategy initiates new positions, exits several in Q1
Allspring Global Investments Holdings LLC Has $77.78 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages
Assenagon Asset Management S.A. Decreases Stock Position in BridgeBio Pharma, Inc. $BBIO
Acoramidis Significantly Reduces the Risk of All-Cause and Cardiovascular Mortality in Patients with ATTR-CM through Month 54
BridgeBio Submits NDA to FDA for BBP-418 for Individuals Living with LGMD2I/R9
BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions
Central Pacific Bank Trust Division Makes New $789,000 Investment in BridgeBio Pharma, Inc. $BBIO
Can Alnylam's Pipeline Drugs Sustain Long-Term Growth Ahead?
Neil Kumar Sells 40,000 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock
Cinctive Capital Management LP Sells 98,688 Shares of BridgeBio Pharma, Inc. $BBIO
BridgeBio Pharma Eyes First Treatment For Rare Muscle Disorder As Trial Data Shows Early Progress
Equities Analysts Set Expectations for BBIO Q1 Earnings
BridgeBio's Rare-Disease Pipeline Sparks Growth Buzz
Victory Capital Management Inc. Purchases 141,800 Shares of BridgeBio Pharma, Inc. $BBIO
Andrea Ellis Sells 64,921 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of “Moderate Buy” by Brokerages
American Century Companies Inc. Has $55.92 Million Stock Holdings in BridgeBio Pharma, Inc. $BBIO
DNB Asset Management AS Acquires Shares of 10,423 BridgeBio Pharma, Inc. $BBIO
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
Aisling Capital Management LP Has $316.29 Million Position in BridgeBio Pharma, Inc. $BBIO
BridgeBio outlines transition to cash generation by 2028 with $600M profit target, driven by pipeline advances and Attruby growth
BridgeBio Pharma GAAP EPS of -$1.00 misses by $0.33, revenue of $154.2M beats by $5.13M
BridgeBio Pharma (BBIO) Reports Q4 Loss, Beats Revenue Estimates
BridgeBio Pharma, Inc. (BBIO) Q4 2025 Earnings Call Transcript
BridgeBio Reports Fourth Quarter and Full Year 2025 Financial Results and Commercial Updates
Here are the major earnings after the close Tuesday
Rare disease pharmas could benefit from FDA guidance to accelerate development
BridgeBio to Participate in March Investor Conferences
BridgeBio to Report Fourth Quarter and Full Year 2025 Financial Results and Business Update on February 24, 2026 at 4:30 pm ET
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) CEO Sells $2,877,600.00 in Stock
BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript
BridgeBio Pharma shares rise on ‘compelling' Phase 3 trial results for achondroplasia drug
BridgeBio Pharma (BBIO) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
BridgeBio Pharma shares rise on ‘compelling’ Phase 3 trial results for achondroplasia drug
BridgeBio Unveils Positive Results For Its Most 'Hotly Debated' Phase 3 Drug
BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
Baader Bank Aktiengesellschaft Takes Position in BridgeBio Pharma, Inc. $BBIO
Buy the Dip on This Biotech Stock After Recent Fall
BridgeBio Pharma (BBIO) Surges 6.8%: Is This an Indication of Further Gains?
BridgeBio: Initiating At A Neutral Rating, Stock Priced At Perfection
BridgeBio Pharma (NASDAQ:BBIO) Shares Gap Up – Still a Buy?
CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. $BBIO Shares Sold by Harvey Capital Management Inc.
BridgeBio Pharma, Inc. $BBIO Shares Sold by Emerald Advisers LLC
BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
BridgeBio Pharma, Inc. (BBIO) Presents at 44th Annual J.P. Morgan Healthcare Conference Prepared Remarks Transcript
BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
BridgeBio Pharma, Inc. (BBIO) Discusses Achondroplasia Pathophysiology, Unmet Needs, and PROPEL 3 Infigratinib Phase 3 Study Transcript
BridgeBio to Participate in the J.P. Morgan Healthcare Conference
BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
BridgeBio Has More Room To Run
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of “Moderate Buy” by Brokerages
Assenagon Asset Management S.A. Trims Stake in BridgeBio Pharma, Inc. $BBIO
Neil Kumar Sells 30,011 Shares of BridgeBio Pharma (NASDAQ:BBIO) Stock
Frontier Capital Management Co. LLC Sells 233,538 Shares of BridgeBio Pharma, Inc. $BBIO
Federated Hermes Inc. Takes Position in BridgeBio Pharma, Inc. $BBIO
Edgestream Partners L.P. Makes New $1.92 Million Investment in BridgeBio Pharma, Inc. $BBIO
American Century Companies Inc. Buys 62,646 Shares of BridgeBio Pharma, Inc. $BBIO
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Consensus Rating of “Moderate Buy” by Analysts
BridgeBio to Participate in December Investor Conferences
Biotech Stock Could Turn 4-Year Peak Into Records
BridgeBio Pharma: Set For New Commercial Launches After Trial Successes
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)